注意缺陷多动障碍的转录组风险评分
该研究基于38,691例ADHD患者和186,843名对照的全基因组关联分析(GWAS)荟萃数据,结合14个基因表达参考面板(涵盖多脑组织和全血)进行转录组关联研究(TWAS),并据此构建转录组风险评分(TRS)。结果显示ADHD患者外周血单核细胞的TRS负荷高于对照,TRS与ADHD多基因风险评分(PRS)不相关,且TRS联合PRS较单用PRS显著提高解释方差比例。
要点
- ADHD患者外周血单核细胞的转录组风险评分(TRS)负荷显著高于对照。
- TRS与ADHD多基因风险评分(PRS)不相关,两者联合较单用PRS显著提高解释方差。
- 基于多脑区表达谱构建的TRS与ADHD存在关联证据。
核心结论
- ADHD与基于多脑区表达谱构建的转录组风险评分(TRS)存在关联,患者TRS负荷高于对照。
- TRS与ADHD多基因风险评分(PRS)不相关,联合PRS可显著提高解释方差比例。
研究设计与样本
- 基于38,691例ADHD患者和186,843名对照的GWAS荟萃分析进行TWAS,使用14个基因表达参考面板(多脑组织和全血)。
- 基于TWAS结果选基因并在ADHD患者与对照的外周血单核细胞中构建TRS。
主要发现
- ADHD患者携带的TRS负荷高于对照,TRS与ADHD关联证据来自多个脑区的表达谱。
- TRS与ADHD的PRS不相关,TRS联合PRS较单用PRS显著提高解释方差比例。
关键数值与推荐
- ADHD患者外周血单核细胞的TRS负荷高于对照。
- TRS与PRS不相关,联合模型较PRS-only模型显著提高解释方差比例。
临床怎么用
- 支持血液基因表达谱与遗传谱在ADHD风险预测中的互补潜力。
- 提示基因表达信息可用于ADHD风险预测并深入理解其分子机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Attention deficit/hyperactivity disorder (ADHD) is a highly heritable neurodevelopmental disorder. We performed a transcriptome-wide association study (TWAS) using the latest genome-wide association study (GWAS) meta-analysis, in 38,691 individuals with ADHD and 186,843 controls, and 14 gene-expression reference panels across multiple brain tissues and whole blood. Based on TWAS results, we selected subsets of genes and constructed transcriptomic risk scores (TRSs) for the disorder in peripheral blood mononuclear cells of individuals with ADHD and controls. We found evidence of association between ADHD and TRSs constructed using expression profiles from multiple brain areas, with individuals with ADHD carrying a higher burden of TRSs than controls. TRSs were uncorrelated with the polygenic risk score (PRS) for ADHD and, in combination with PRS, improved significantly the proportion of variance explained over the PRS-only model. These results support the complementary predictive potential of genetic and transcriptomic profiles in blood and underscore the potential utility of gene expression for risk prediction and deeper insight in molecular mechanisms underlying ADHD.
引用
- Cabana-Domínguez J, Llonga N, Arribas L, et al. Transcriptomic risk scores for attention deficit/hyperactivity disorder. Mol Psychiatry. 2023. PMID: 37537283. doi:10.1038/s41380-023-02200-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。